Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: This is two cents stuff, not DD

Opps sorry about the prior blank post.

Toshiba and NEC separately requested patent review. Based on that, one would expect that the primary defense is prior art/obviousness.  Are we now saying prior art/obiousness is no longer part of the J2 defense?  I read through the defenses and did not see it, but not sure if I would recognize it. Can anyone with expertise in legaleze and familiar with all the filings please confirm that this is indeed the case. Many thanks in advance. opty

Share
New Message
Please login to post a reply